Combination of SRC kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases

Details for Australian Patent Application No. 2004263095 (hide)

Owner Bristol-Myers Squibb Company

Inventors Lee, Francis Y. F.

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-B-2004263095

PCT Pub. Number WO2005/013983

Priority 60/485,779 09.07.03 US

Filing date 9 July 2004

Wipo publication date 17 February 2005

Acceptance publication date 29 October 2009

International Classifications

A61K 31/426 (2006.01) - 1,3-Thiazoles

A61K 31/427 (2006.01) - not condensed and containing further heterocyclic rings

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

Event Publications

2 February 2006 PCT application entered the National Phase

  PCT publication WO2005/013983 Priority application(s): WO2005/013983

29 October 2009 Application Accepted

  Published as AU-B-2004263095

25 February 2010 Standard Patent Sealed

3 February 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004263097-System and method for determining concentration of sterilant

2004263094-Programmed immune responses using a vaccination node